💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Sangamo BioSciences, Inc. (SGMO)
« Back to company indexSGMO Chatter Timeline
Stock Ticker for SGMO
Most Active Tweeters for SGMO
| User | Tweets |
|---|---|
| @_B_I_O_T_E_C_H_ | 14 |
| @MitchellReed09 | 8 |
| @Tickeron | 6 |
| @mchilberg | 6 |
| @Biotech2050 | 4 |
Recent Tweets for SGMO
 |
@MitchellReed09 RT @MarcJacksonLA: $SGMO Sangamo Therapeutics Given Consensus Rating of "Buy" by Brokerages | $18.40 Average PT https://t.co/NKb5pRLCDo htt… 3:01am |
 |
@MarcJacksonLA $SGMO Sangamo Therapeutics Given Consensus Rating of "Buy" by Brokerages | $18.40 Average PT https://t.co/NKb5pRLCDo https://t.co/WzzvWd9DTb January 22nd 2022, 10:01pm |
 |
@Tickeron $SGMO's in Downtrend: Moving Average Convergence Divergence (MACD) Histogram crosses below signal line. View odds f… https://t.co/PbBZOAEK8Q January 22nd 2022, 7:01pm |
 |
@mattyjc @michaeldurnin1 Agree! And now Fabry is going to be just as, if not more valuable than Heme A to $SGMO. I suspect… https://t.co/KYfVrpsD7d January 22nd 2022, 1:01pm |
|
@mattyjc @michaeldurnin1 I’ve had my $SGMO shares so long I’d probably watch them go to zero before I’d sell. Didn’t sell an… https://t.co/kpeJrPjjxS January 22nd 2022, 12:01pm |
 |
@michaeldurnin1 @mattyjc I am in $RBLX and $SGMO , and I think I’ll leave it there for the next 6months think Both are excellent 1-… https://t.co/odg6yI584y January 22nd 2022, 9:01am |
 |
@Biotech2050 RT @_B_I_O_T_E_C_H_: $SGMO #BASE #EDITING Nuclear and mitochondrial DNA editing with #zinc #finger deaminases ZFDs with enhanced efficiency… January 22nd 2022, 9:01am |
 |
@_B_I_O_T_E_C_H_ $SGMO #BASE #EDITING Nuclear and mitochondrial DNA editing with #zinc #finger deaminases ZFDs with enhanced efficie… https://t.co/eCdqQBlWGH January 22nd 2022, 9:01am |
 |
@QuantchaIdeas StockTwits Trending Alert: Trading recent interest in SANGAMO THERAPEUTICS INC. COMMON STOCK $SGMO https://t.co/zrqkODtfXp January 22nd 2022, 5:01am |
 |
@retailbiotech $SGMO best gene therapy and gene edited. January 21st 2022, 2:01pm |
|
@michaeldurnin1 @mchilberg @Biotech2050 Good news , so that means $SGMO down 10% today lol ? January 21st 2022, 2:01pm |
 |
@smargach @_B_I_O_T_E_C_H_ The crack IR team at $sgmo hard at work. January 20th 2022, 3:01pm |
|
@_B_I_O_T_E_C_H_ RT @_B_I_O_T_E_C_H_: $SGMO Sangamo CEO says preclinical studies moving forward 'beautifully' https://t.co/xarOmB2idB January 20th 2022, 3:01pm |
 |
@inoritrade $SGMO Waiting for BUY signal on SGMO with https://t.co/WBARPaspdC https://t.co/bKvjRYF1hW January 20th 2022, 3:01pm |
|
@_B_I_O_T_E_C_H_ RT @_B_I_O_T_E_C_H_: $SGMO Sangamo COO sees 'important catalysts' over next 12 month #agency will be #lifted #shortly and we will continu… January 20th 2022, 2:01pm |
 |
@B_rizzle87 @_B_I_O_T_E_C_H_ It is illegal for $SGMO stock to go up. January 20th 2022, 12:01pm |
|
@_B_I_O_T_E_C_H_ $SGMO Sangamo COO sees 'important catalysts' over next 12 month #agency will be #lifted #shortly and we will cont… https://t.co/PrlRpQMhcF January 20th 2022, 12:01pm |
|
@_B_I_O_T_E_C_H_ $SGMO Sangamo CEO says preclinical studies moving forward 'beautifully' https://t.co/xarOmB2idB January 20th 2022, 12:01pm |
|
@MitchellReed09 RT @InvestorVillage: Trending: $SGMO COO Mark McClung says company anticipates clinical hold on Hemophilia A trial (in partnership with $P… January 19th 2022, 9:01pm |
 |
@maximtrade134 RT @newsinthemarket: Clinical hold on Hemophilia A program should be lifted soon, Sangamo COO says $SGMO January 19th 2022, 9:01pm |
 |
@Gambiste1 RT @_B_I_O_T_E_C_H_: Meet Sangamo: Fly exclusive interview with $SGMO CEO Sandy Macrae, COO Mark McClung https://t.co/28zNsPuMiJ January 19th 2022, 9:01pm |
 |
@EVgirl66 RT @_B_I_O_T_E_C_H_: FLY: $PFE $SGMO Clinical hold on Hemophilia A program should be lifted soon, Sangamo COO says January 19th 2022, 9:01pm |
 |
@InvestorVillage Trending: $SGMO COO Mark McClung says company anticipates clinical hold on Hemophilia A trial (in partnership with… https://t.co/SXB5xqoM1X January 19th 2022, 8:01pm |
|
@_B_I_O_T_E_C_H_ Meet Sangamo: Fly exclusive interview with $SGMO CEO Sandy Macrae, COO Mark McClung https://t.co/28zNsPuMiJ January 19th 2022, 7:01pm |
 |
@BioWino petri dish say what? $sgmo https://t.co/PwdxdIv2Ho January 19th 2022, 7:01pm |
 |
@vtmtrading Sangamo CEO says success in CAR-TREG space more 'than just science' $SGMO January 19th 2022, 6:01pm |
|
@_B_I_O_T_E_C_H_ RT @newsinthemarket: Sangamo 'an unusual company' with deep portfolio, CEO says $SGMO January 19th 2022, 6:01pm |
|
@_B_I_O_T_E_C_H_ FLY: $PFE $SGMO Clinical hold on Hemophilia A program should be lifted soon, Sangamo COO says January 19th 2022, 6:01pm |
 |
@newsinthemarket Success in CAR-TREG more than just science, Sangamo CEO says $SGMO January 19th 2022, 6:01pm |
|
@newsinthemarket Clinical hold on Hemophilia A program should be lifted soon, Sangamo COO says $SGMO January 19th 2022, 6:01pm |
|
@newsinthemarket Sangamo expects to dose first patients by mid-2022 in TX200 trial, COO says $SGMO January 19th 2022, 6:01pm |
|
@newsinthemarket Sangamo 'an unusual company' with deep portfolio, CEO says $SGMO January 19th 2022, 6:01pm |
|
@BioWino RT @algobotnews: Sangamo 'an unusual company' with deep portfolio, CEO says $SGMO January 19th 2022, 6:01pm |
|
@BioWino RT @algobotnews: Clinical hold on Hemophilia A program should be lifted soon, Sangamo COO says $SGMO January 19th 2022, 6:01pm |
 |
@TradeWithAlerts Nice print for $SGMO Size: 285236 Price: 5.93 Amount: $1,691,449.48 Time: 1600 See more: https://t.co/hnsHyqw7d5 Jo… https://t.co/E6SYaLEJNP January 18th 2022, 9:01pm |
 |
@auditor112017 @RNAiAnalyst Is $ions prevented from going the allele-specific route? They have the ASOs for them. $sgmo January 18th 2022, 5:01pm |
 |
@STOCKMASTERJAY $SGMO ITS TIME FOR A DEAL @SangamoTx January 18th 2022, 5:01pm |
 |
@ironicpoor RT @Tickeron: $SGMO's in Downtrend: Moving Average Convergence Divergence (MACD) Histogram crosses below signal line. View odds for this an… January 17th 2022, 9:01pm |
|
@Tickeron $SGMO's in Downtrend: Moving Average Convergence Divergence (MACD) Histogram crosses below signal line. View odds f… https://t.co/Ho4DiMErLB January 17th 2022, 9:01pm |
|
@MitchellReed09 RT @Ba4Saso: $SGMO Bullish pattern building. Chart by https://t.co/z6vAd7dl0q https://t.co/MpMHM5v1Ly January 17th 2022, 5:01pm |
 |
@Ba4Saso $SGMO Bullish pattern building. Chart by https://t.co/z6vAd7dl0q https://t.co/MpMHM5v1Ly January 17th 2022, 4:01pm |
|
@Tickeron $SGMO's in Downtrend: Moving Average Convergence Divergence (MACD) Histogram crosses below signal line. View odds f… https://t.co/JXBpYxDJhz January 15th 2022, 9:01pm |
 |
@A1Syad $SGMO Awaiting Buy Signal. Free 7 Day Trial at https://t.co/1MjnDHV7ua https://t.co/nitwtLec4k January 15th 2022, 8:01pm |
 |
@ChartMill The technical rating of $SGMO is bad and it also does not present a quality setup at the moment.… https://t.co/KjVjmY3e8m January 15th 2022, 7:01pm |
|
@inoritrade $SGMO Waiting for BUY signal on SGMO with https://t.co/WBARPaK0Cc https://t.co/k4WTvrFPZJ January 14th 2022, 9:01pm |
|
@STOCKMASTERJAY $SGMO IM A GLUTTON FOR PUNISHMENT .. BOUGHT MORE CALLS .. AND IM GONNA KEEP GOING .. SOMETIMES ITS JUST ABOUT A GUT FEELING .. January 14th 2022, 8:01pm |
|
@MitchellReed09 RT @mchilberg: I just placed buy order for Jan 2024 $5s and have a limit order to buy shares in $SGMO as well. May not be over but clearly… January 14th 2022, 7:01pm |
 |
@mchilberg I just placed buy order for Jan 2024 $5s and have a limit order to buy shares in $SGMO as well. May not be over bu… https://t.co/8DVYgOSG77 January 14th 2022, 5:01pm |
|
@STOCKMASTERJAY @mchilberg is it time to load 1,000 $sgmo calls or is this dog dead January 14th 2022, 5:01pm |
|
@Ba4Saso $SGMO Awaiting Buy Signal. Chart by https://t.co/z6vAd7dl0q https://t.co/4nkElko42s January 14th 2022, 1:01pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2022. All rights reserved.
DrugPatentWatch Video Training
Decision-making for generic drug entry and branded drug lifecycle management
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
This course answers the following questions to help you adapt:
- ✓ When will key drug patents expire?
- ✓ How can I find, evaluate, and plan for generic market entry opportunities?
- ✓ How can I find proprietary out-of-court settlements and deal terms?